Australië - Engels - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - ephedrine hydrochloride, quantity: 30 mg - injection, solution - excipient ingredients: water for injections - ephedrine hydrochloride injection is indicated in the treatment of hypotension secondary to spinal anaesthesia.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - ephedrine hydrochloride, quantity: 30 mg - injection, solution - excipient ingredients: sodium chloride; sodium citrate; citric acid; water for injections - ephedrine interpharma injection is indicated in the treatment of hypotension secondary to spinal anaesthesia.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - ephedrine hydrochloride, quantity: 30 mg - injection, solution - excipient ingredients: water for injections - ephedrine hydrochloride injection is indicated in the treatment of hypotension secondary to spinal anaesthesia.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - ephedrine hydrochloride -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ephedrine sulfate -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - ephedrine hydrochloride, quantity: 30 mg - injection, solution - excipient ingredients: citric acid monohydrate; water for injections; sodium chloride; dilute hydrochloric acid; sodium hydroxide; sodium citrate - treatment of hypotension secondary to spinal anaesthesia

Australië - Engels - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - ephedrine hydrochloride, quantity: 30 mg - injection, solution - excipient ingredients: citric acid monohydrate; dilute hydrochloric acid; water for injections; sodium hydroxide; sodium chloride; sodium citrate - treatment of hypotension secondary to spinal anaesthesia

Israël - Engels - Ministry of Health

cts ltd - ephedrine hydrochloride - solution for injection - ephedrine hydrochloride 50 mg/ml - ephedrine - ephedrine hydrochloride is used in the prevention and treatment of hypotension from spinal or epidural anaesthesia and during general anaesthesia, with or without a reduction in the heart rate, administered for a surgical or obstetric procedure.

Verenigde Staten - Engels - NLM (National Library of Medicine)

endo usa, inc. - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate 50 mg in 1 ml - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none r isk summary limited published data on the use of ephedrine sulfate are insufficient to determine a drug associated risk of major birth defects or miscarriage. however, there are clinical considerations [see clinical considerations] . animal reproduction studies have not been conducted with ephedrine sulfate. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown.  all pregnancies have a background risk of birth defect, loss, or other adverse outcomes.  in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. c linical considerations fetal/neonatal adverse reactions cases of potential metabolic acidosis in newborns at delivery with maternal ephedrine exposure have been reported in the literature. these reports describe umbilical artery ph of ≤7.2 at the time of delivery [see clinical pharmacology 12.3] . monitoring of the newborn for signs and symptoms of metabolic acidosis may be required. monitoring of infant’s acid-base status is warranted to ensure that an episode of acidosis is acute and reversible. r isk summary limited published literature reports that ephedrine is present in human milk. however, no information is available on the effects of the drug on the breastfed infant or the effects of the drug on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ephedrine sulfate injection and any potential adverse effects on the breastfed child from ephedrine sulfate injection or from the underlying maternal condition. safety and effectiveness in pediatric patients have not been established. clinical studies of ephedrine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. this drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. ephedrine and its metabolite are excreted in urine. in patients with renal impairment, excretion of ephedrine is likely to be affected with a corresponding increase in elimination half-life, which will lead to slow elimination of ephedrine and consequently prolonged pharmacological effect and potentially adverse reactions. monitor patients with renal impairment carefully after the initial bolus dose for adverse events.

Verenigde Staten - Engels - NLM (National Library of Medicine)

nexus pharmaceuticals inc - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate 50 mg in 1 ml - ephedrine sulfate injectionn, usp is indicated in the treatment of allergic disorders, such as bronchial asthma the drug has long been used as a pressor agent, particularly during spinal anesthesia when hypotensionn frequently ooccurs. in stokes-adams syndromeme with complete heart block, ephedrine has a value similar to that of epinephrine. it is indicated as a central nervous system stimulant in narcolepsy and depressive states. it is also used in myasthenia gravis. allergic reactions to ephedrine sulfate are rare. the hypersensitivity, if known, is a specific contraindication. patients hypersensitive to other sympathomimetics may also be hypersensitive to ephedrine sulfate. prolonged abuse of ephedrine sulfate injection, usp can lead to symptoms of paranoid schizophrenia. when this occurs, patients exhibit such physical signs as tachycardia, poor nutrition and hygiene, fever, cold sweat and dilated pupils. some measure of tolerance may develop with prolonged or excessive use but addiction does not occur. t